AZD0186 Safety and Pharmacokinetics Study in Adult Participants

Unknown Phase 1 NCT05694741

Study Description

This study evaluates AZD0186, an investigational drug, in healthy adults to determine its safety, tolerability, and pharmacokinetics. The study employs a randomized, single-blind, sponsor-open, placebo-controlled, SAD sequential group design across four parts. Each part includes a Screening Period and a Treatment Period during which subjects will be resident at the Clinical Unit for at least 48 hours after IMP administration. The study also includes a Follow-up Visit, scheduled 7-14 days post last IMP dose. The study aims to determine the safety and pharmacokinetics of AZD0186 in adult participants.

Study Details

Registry ID:
NCT05694741
Conditions:
Type 2 Diabetes
Phase:
Phase 1
Target Enrollment:
31 participants
Start Date:
Age Range:
18–55 years
Healthy Volunteers:
No

Study Locations (1 site)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →